## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 1 of 2

Complete if Known					
Application Number	10/594,473				
Filing Date	November 13, 2007				
First Named Inventor	Xian-Ming Zeng				
Art Unit	1615				
Examiner Name	Humera N. Sheikh				
Attorney Docket No.	TEVE-124US				

			U.S. PATENT D	OCUMENTS		
Examiner Cite		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials*	No.1	Number - Kind Code <sup>2 (if known)</sup>	(MM-DD-YYYY)	Applicant of Cited Document	Figures Appear	
1 15 1		US-2004-0258626	12-23-2004	Zeng		
	-	US-2005-0158248	07-21-2005	Zeng		
		US-2006-0292083	12-28-2006	Zeng		
		US-				
		US-				
		US-				
		US-				
	1	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
· · · · · · · · · · · · · · · · · · ·		US-				
		US-				
• • • • • • • • • • • • • • • • • • • •		US-	<del></del>			

FOREIGN PATENT DOCUMENTS						
	<u> </u>	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Clte No. <sup>1</sup>	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5 (If known)</sup>	Publication Date (MM-DD-YYYY)	Applicant of Cited Document	Passages or Relevant Figures Appear	T <sup>6</sup>
		WO 03/024396	03-27-2003	Glaxo Group Limited		
····						

	· · · · · · · · · · · · · · · · · · ·	<u> </u>	
Examiner	/Randeep Singh/	Date	06/16/2011
Signature		 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional).

<sup>2</sup>See Kind Codes of USPTO Patent Documents at <a href="http://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04.

<sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard St.3).

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>&</sup>lt;sup>5</sup>Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST.16 if possible.

Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** 

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 2 of 2

Complete if Known				
Application Number	10/594,473	·		
Filing Date	November 13, 2007			
First Named Inventor	Xian-Ming Zeng			
Art Unit	1614			
Examiner Name	Not Yet Assigned			
Attorney Docket No.	TEVE-124US			

		NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1			
		GILLIAN M. KEATING <i>et al.</i> , "Airmax™1 A Multi-Does Dry Powder Inhaler," Adis New Device Profile, (2002), Vol. 62, no. 13, pp. 1887-1895.		
		XIAN MING ZENG et al., "The Influence of Lactose Carrier on the Content Homogeneity and Dispersibility of Beclomethasone Dipropionate from Dry Powder Aerosols," International Journal of Pharmaceutics, (2000), Vol. 197, pp. 41-52		
		Supplemental European Search Report EP 04 78 2768 dated March 18, 2009.		
<del> </del>				

Examiner	/Randeep Singh/	Date	06/16/2011	
Signature	/ tandoop ong.	Considered		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

1 Applicant's unique citation designation number (optional).

<sup>&</sup>lt;sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.